Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company's drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NYSEMKT:CANF
- CUSIP: N/A
- Web: www.canfite.co.il
- 50 Day Moving Avg: $1.84
- 200 Day Moving Avg: $2.04
- Trailing P/E Ratio: N/A
- P/E Growth: 0.0000
- Net Margins: -2,453.03%
- Return on Equity: -57.94%
- Return on Assets: -32.52%
Frequently Asked Questions for Can Fite Biopharma Ltd (NYSEMKT:CANF)
What is Can Fite Biopharma Ltd's stock symbol?
Can Fite Biopharma Ltd trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "CANF."
How were Can Fite Biopharma Ltd's earnings last quarter?
Can Fite Biopharma Ltd (NYSEMKT:CANF) posted its quarterly earnings data on Tuesday, May, 31st. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.03. Can Fite Biopharma Ltd had a negative net margin of 2,453.03% and a negative return on equity of 57.94%. View Can Fite Biopharma Ltd's Earnings History.
Where is Can Fite Biopharma Ltd's stock going? Where will Can Fite Biopharma Ltd's stock price be in 2017?
2 brokers have issued twelve-month price targets for Can Fite Biopharma Ltd's stock. Their forecasts range from $6.00 to $6.00. On average, they expect Can Fite Biopharma Ltd's stock price to reach $6.00 in the next year. View Analyst Ratings for Can Fite Biopharma Ltd.
Who are some of Can Fite Biopharma Ltd's key competitors?
Some companies that are related to Can Fite Biopharma Ltd include Sierra Oncology (SRRA), KemPharm (KMPH), Galmed Pharmaceuticals Ltd (GLMD), CASI Pharmaceuticals (CASI), Zosano Pharma Corp (ZSAN), ContraFect Corp (CFRX), Eiger Biopharmaceuticals (EIGR), Flex Pharma (FLKS), GTx (GTXI), Bioline RX Ltd (BLRX), ADMA Biologics (ADMA), Prima BioMed Ltd (PBMD), XOMA (XOMA), vTv Therapeutics (VTVT), TRACON Pharmaceuticals (TCON), Inotek Pharmaceuticals Corp (ITEK), OvaScience (OVAS) and Burcon NutraScience Corp (BUR).
How do I buy Can Fite Biopharma Ltd stock?
Shares of Can Fite Biopharma Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
Earnings History for Can Fite Biopharma Ltd (NYSEMKT:CANF)Earnings History by Quarter for Can Fite Biopharma Ltd (NYSEMKT:CANF)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Current Year EPS Consensus Estimate: $-0.31 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS
Dividend History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Latest Headlines for Can Fite Biopharma Ltd (NYSEMKT:CANF)